Metabolomic signatures of aggressive prostate cancer

Current diagnostic techniques have increased the detection of prostate cancer; however, these tools inadequately stratify patients to minimize mortality. Recent studies have identified a biochemical signature of prostate cancer metastasis, including increased sarcosine abundance. This study examined the association of tissue metabolites with other clinically significant findings.

[1]  R. Weiss,et al.  Urine metabolomic analysis identifies potential biomarkers and pathogenic pathways in kidney cancer. , 2011, Omics : a journal of integrative biology.

[2]  T. Veenstra,et al.  Global proteomics and metabolomics in cancer biomarker discovery. , 2011, Journal of separation science.

[3]  Nallasivam Palanisamy,et al.  Urine TMPRSS2:ERG Fusion Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSA , 2011, Science Translational Medicine.

[4]  A. Haese*,et al.  High incidence of prostate cancer detected by saturation biopsy after previous negative biopsy series. , 2006, European urology.

[5]  Amit Patel,et al.  Prostate cancer detection with office based saturation biopsy in a repeat biopsy population. , 2004, The Journal of urology.

[6]  A. Whittemore,et al.  A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. , 2005, American journal of human genetics.

[7]  J. Capala,et al.  Sarcosine induces increase in HER2/neu expression in androgen-dependent prostate cancer cells , 2011, Molecular Biology Reports.

[8]  Pingkun Yan,et al.  Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging. , 2011, The Journal of urology.

[9]  J. F. Cooper,et al.  The role of citric acid in the physiology of the prostate: a preliminary report. , 1958, Transactions. American Urological Association. Western Section.

[10]  J. McDunn,et al.  Cancer detection and biopsy classification using concurrent histopathological and metabolomic analysis of core biopsies , 2012, Genome Medicine.

[11]  T. Veenstra,et al.  Is sarcosine a biomarker for prostate cancer? , 2011, Journal of separation science.

[12]  T. Hara,et al.  PET imaging of prostate cancer using carbon-11-choline. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  T. Wheeler,et al.  Fresh tissue harvest for research from prostatectomy specimens , 1994, The Prostate.

[14]  Bruce J Trock,et al.  Application of metabolomics to prostate cancer. , 2011, Urologic oncology.

[15]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[16]  M. Milburn,et al.  Metabolomic profiling can predict which humans will develop liver dysfunction when deprived of dietary choline , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[17]  A. Pegg,et al.  Mechanisms and regulation of polyamine and putrescine biosynthesis in male genital glands and other tissues of mammals. , 1969, Advances in enzyme regulation.

[18]  R. Yantiss,et al.  Metabolic Profiling, a Noninvasive Approach for the Detection of Experimental Colorectal Neoplasia , 2012, Cancer Prevention Research.

[19]  Misop Han,et al.  Predicting 15-year prostate cancer specific mortality after radical prostatectomy. , 2011, The Journal of urology.

[20]  K. Kuroiwa,et al.  The important role of glycine N-methyltransferase in the carcinogenesis and progression of prostate cancer , 2011, Modern Pathology.

[21]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[22]  L. Egevad,et al.  The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma , 2005, The American journal of surgical pathology.

[23]  A. Whittemore,et al.  Multiple regions within 8q24 independently affect risk for prostate cancer , 2007, Nature Genetics.

[24]  X. Yao,et al.  Efforts to resolve the contradictions in early diagnosis of prostate cancer: a comparison of different algorithms of sarcosine in urine , 2011, Prostate Cancer and Prostatic Diseases.

[25]  Alan W Partin,et al.  Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. , 2007, Urology.

[26]  R. Eliasson.  ACCURATE DETERMINATION OF GLUCOSE IN HUMAN SEMEN , 1965 .

[27]  James A Hanley,et al.  20-year outcomes following conservative management of clinically localized prostate cancer. , 2005, JAMA.

[28]  P. Clark,et al.  Serum Methionine Metabolites Are Risk Factors for Metastatic Prostate Cancer Progression , 2011, PloS one.

[29]  Corey D. DeHaven,et al.  Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. , 2009, Analytical chemistry.

[30]  Tak W. Mak,et al.  Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations , 2010, The Journal of experimental medicine.

[31]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[32]  Anastasia K Yocum,et al.  The role of sarcosine metabolism in prostate cancer progression. , 2013, Neoplasia.

[33]  D. Gleason.  Classification of prostatic carcinomas. , 1966, Cancer chemotherapy reports.

[34]  M. Cooperberg,et al.  UC San Francisco UC San Francisco Previously Published Works Title Active surveillance for prostate cancer : Progress and promise , 2011 .

[35]  M. Ruiz-Echevarría,et al.  The Tumor Suppressor Activity of the Transmembrane Protein with Epidermal Growth Factor and Two Follistatin Motifs 2 (TMEFF2) Correlates with Its Ability to Modulate Sarcosine Levels* , 2011, The Journal of Biological Chemistry.

[36]  Ronald Aylmer Sir Fisher,et al.  Statistical Methods, Experimental Design, and Scientific Inference , 1990 .

[37]  John T. Wei,et al.  Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression , 2009, Nature.

[38]  Kurt Miller,et al.  Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression. , 2011, The Journal of urology.

[39]  P. Ditonno,et al.  Serum sarcosine increases the accuracy of prostate cancer detection in patients with total serum PSA less than 4.0 ng/ml , 2012, The Prostate.

[40]  J. Isaacs,et al.  Prostate‐specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells , 2000, The Prostate.

[41]  Gerald C. Chu,et al.  SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression , 2011, Nature.

[42]  G. Kristiansen,et al.  Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. , 2010, European urology.

[43]  Pär Stattin,et al.  Metabolomic Characterization of Human Prostate Cancer Bone Metastases Reveals Increased Levels of Cholesterol , 2010, PloS one.

[44]  Gleason Df.  Classification of prostatic carcinomas. , 1966 .

[45]  Anne M. Evans,et al.  Organization of GC/MS and LC/MS metabolomics data into chemical libraries , 2010, J. Cheminformatics.

[46]  Steven Piantadosi,et al.  Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. , 2003, The Journal of urology.

[47]  Christina Bougatsos,et al.  Screening for Prostate Cancer: A Review of the Evidence for the U.S. Preventive Services Task Force , 2011, Annals of Internal Medicine.

[48]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[49]  Zhon-Yin Zhang.  Faculty Opinions recommendation of Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. , 2009 .

[50]  K. Schulman,et al.  Changes in initial treatment for prostate cancer among Medicare beneficiaries, 1999-2007. , 2012, International journal of radiation oncology, biology, physics.

[51]  A. Brash,et al.  15-lipoxygenase-2 (15-LOX-2) is expressed in benign prostatic epithelium and reduced in prostate adenocarcinoma. , 1999, The American journal of pathology.

[52]  M. Blankenstein,et al.  Serum sarcosine is not a marker for prostate cancer , 2010, Annals of clinical biochemistry.

[53]  D. Födinger,et al.  High expression of a CD38-like molecule in normal prostatic epithelium and its differential loss in benign and malignant disease. , 1995, The Journal of urology.

[54]  P. Carroll,et al.  Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. , 1996, Radiology.

[55]  Rodolfo Montironi,et al.  Contemporary Role of Systematic Prostate Biopsies: Indications, Techniques, and Implications for Patient Care , 2013 .

[56]  P. Fearnhead,et al.  Genome-wide association study of prostate cancer identifies a second risk locus at 8q24 , 2007, Nature Genetics.